Claude M Wischik Selected Research

Neurodegenerative Diseases (Neurodegenerative Disease)

3/2024	LETC inhibits α-Syn aggregation and ameliorates motor deficiencies in the L62 mouse model of synucleinopathy.
1/2022	Structural Identification of Individual Helical Amyloid Filaments by Integration of Cryo-Electron Microscopy-Derived Maps in Comparative Morphometric Atomic Force Microscopy Image Analysis.
1/2018	Modeling Prion-Like Processing of Tau Protein in Alzheimer's Disease for Pharmaceutical Development.
1/2017	A Protein Aggregation Inhibitor, Leuco-Methylthioninium Bis(Hydromethanesulfonate), Decreases α-Synuclein Inclusions in a Transgenic Mouse Model of Synucleinopathy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Claude M Wischik Research Topics

Disease

37	Alzheimer Disease (Alzheimer's Disease) 04/2024 - 11/2008
8	Tauopathies 04/2024 - 04/2015
7	Parkinson Disease (Parkinson's Disease) 03/2024 - 01/2017
6	Dementia (Dementias) 04/2024 - 12/2009
5	Synucleinopathies 03/2024 - 01/2017
5	Atrophy 04/2022 - 01/2018
4	Neurodegenerative Diseases (Neurodegenerative Disease) 03/2024 - 01/2017
4	Cognitive Dysfunction 01/2023 - 01/2009
4	Frontotemporal Dementia (Semantic Dementia) 01/2021 - 01/2020
1	Nervous System Diseases (Neurological Disorders) 01/2024
1	Amyloidosis 01/2022
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2021
1	Disease Progression 11/2020
1	Frontotemporal Lobar Degeneration (Degeneration, Frontotemporal Lobar) 01/2020
1	Neuroblastoma 01/2019
1	Motor Disorders 01/2019
1	Neurobehavioral Manifestations 01/2017

Drug/Important Bio-Agent (IBA)

19	tau Proteins (tau Protein)IBA 04/2024 - 01/2015
14	hydromethylthionineIBA 04/2024 - 01/2017
6	Proteins (Proteins, Gene)FDA Link 12/2023 - 12/2009
4	alpha-SynucleinIBA 03/2024 - 12/2009
4	SynucleinsIBA 01/2024 - 01/2017
3	Cholinergic Agents (Cholinergics)IBA 04/2024 - 01/2009
3	Amyloid (Amyloid Fibrils)IBA 01/2022 - 06/2015
2	Cholinesterase Inhibitors (Anticholinesterases)IBA 04/2024 - 01/2020
2	SNARE Proteins (SNAREs)IBA 04/2024 - 12/2009
2	Rivastigmine (Exelon)FDA LinkGeneric 04/2024 - 04/2022
2	Biomarkers (Surrogate Marker)IBA 01/2023 - 11/2020
1	dityrosineIBA 10/2022
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 04/2022
1	Mesylates (Mesylate)IBA 01/2022
1	MCOIBA 01/2021
1	MetalsIBA 01/2021
1	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 01/2021
1	Memantine (Namenda)FDA Link 01/2020
1	Cysteine (L-Cysteine)FDA Link 10/2018
1	Glucose (Dextrose)FDA LinkGeneric 01/2018
1	PrionsIBA 01/2018
1	DisulfidesIBA 11/2017
1	Methylene Blue (Methylthioninium Chloride)FDA Link 12/2016
1	hexamethylpropyleneamine oximeIBA 09/2011
1	Qa-SNARE Proteins (Syntaxin)IBA 12/2009
1	thiazin redIBA 11/2008
1	Amyloid beta-PeptidesIBA 11/2008
1	Coloring Agents (Dyes)IBA 11/2008

Therapy/Procedure

10	Therapeutics 03/2024 - 04/2014
2	Activities of Daily Living (ADL) 01/2018 - 12/2016